kite apc

Wellteq Announces Strategic Partnership in Spain With Frontier Wellness Management / Apotheek Pharma Consulting

  • Wellteq (CSE.WTEQ) (OTC.WTEQF) signs letter of intent (LOI) detailing the general terms of a strategic partnership agreement with Frontier Wellness Management and its operating subsidiary Apotheek Pharma Consulting (FW-APC).
  • FW-APC are focused on marketing health and wellness solutions into their unique network of 140,000 medical professionals in the healthcare, pharmacy, and pharmaceutical markets in Spain.
  • Under the expected terms of a formal strategic partnership agreement, FW-APC will pay an initial EUR100,000 to Wellteq which will be expended on localization, further development, and integration. It is expected that Wellteq will be paid by each customer in accordance with their Software-as-a-Service (SaaS) user pricing.
  • Working with Wellteq's sales and marketing personnel, FW-APC will immediately initiate marketing of the Wellteq application into FW-APC's existing client list.
  • Wellteq will also be tasked with sourcing and integrating third-party applications under the strategic partnership.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

WellteQ Digital Health Inc. (CSE:WTEQ) (OTC:WTEQF) (the "Company" or "Wellteq") is pleased to announce the Company has signed a letter of intent (the "LOI") detailing the general terms of a strategic partnership with Frontier Wellness Management and its operating subsidiary Apotheek Pharma Consulting (FW-APC) in the European Union.

The FW-APC team have a combined 100 years of experience focused on marketing health and wellness solutions into their unique network of 140,000 medical professionals in the healthcare, pharmacy, and pharmaceutical markets in Spain.

Upon execution of a Formal Strategic Partnership Agreement, FW-APC will advance EUR100,000 to Wellteq. This amount will be applied toward application localization, development, and integration. Working with Wellteq sales and marketing personnel, FW-APC will immediately initiate marketing of the Wellteq smartphone application, working with Wellteq sales and marketing personnel, into FW-APC's existing client base. FW-APC will ensure that white label solutions of Wellteq applications will be identified as "powered by Wellteq".

Wellteq will be the technology partner for any required development of the Wellteq solution and for the sourcing and integration of third-party applications / solutions. Where ancillary revenues are generated through the deployed offerings, it is expected that the parties will agree on an equitable distribution of the revenue streams between FW-APC, Wellteq and any integrated third-party solution partners.

Wellteq is initiating European distribution ahead of schedule as part of its geographical expansion plans, reinforcing the market need for globally focused digital health platforms.

"The Spanish healthcare system is more acutely focused on prevention versus treatment when compared to most jurisdictions, and Wellteq fits perfectly within that system while also bringing significant economic benefit to those enterprises adopting the platform," stated John MacPhail, CEO of Frontier Wellness.

"The pandemic has created a demand from our network of clients to improve and increase their digital presence not only for their customers but also for their employees. Wellteq provides a truly unique and universal solution to those needs," said Carles Deulofeu, Managing Director of Apotheek Pharma Consulting.

Scott Montgomery, CEO of Wellteq, said, "Working with Frontier/Apotheek provides a unique and immediate marketing, sales and revenue opportunity for Wellteq's digital health and wellness solutions and fast-tracks our entry into the European Union through a strategic partnership with an organization that has an incredibly deep relationship network already in place."

About Frontier Wellness

Frontier Wellness Management is the parent company of Apotheek Pharma Consulting, a company focused on marketing health and wellness solutions into its unique network of 140,000 medical professionals in the healthcare, pharmacy, and pharmaceutical markets in Spain (ranked "Healthiest Country in the World" by Bloomberg in 2019). Apotheek, based in Barcelona, is works with strategic partners to secure, develop and market innovative and potentially industry disrupting health and wellness products and technologies into its vast network. The primary services of Apotheek include technology procurement, systems analysis, software integration, operational analysis, product integration, market research, regulatory affairs, marketing, and sales management.

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model, Wellteq currently has two main sectors of customers: employers and insurance companies. Wellteq has secured a large multinational portfolio of customers, including UBS, DBS and Bupa Insurance, and reseller partners, like Willis Towers Watson, Advanced Human Imaging and Garmin. Wellteq is developing its newly acquired Internet of Medical Things (IoMT) platform for virtual care applications which will extend the Wellteq continuum of care from preventative wellness through to virtual healthcare.

Investor Contact:

Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888
Sales & Partnership Contact:

stacey@wellteq.co

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×